BOI

FR0000061129

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:17 2024-07-05 EDT			5-day change	1st Jan Change
33.25 ^EUR	+5.39%		+6.06%	-17.33%

07-04	Boiron: changes in governance	CF
04-25	Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Boiron: changes in governance

July 04, 2024 at 07:43 am

Boiron announces a change in its governance, with the appointment of Thierry Boiron as CEO to replace Valérie Lorentz- Poinsot, who is concurrently resigning from her directorship.

Anabelle Flory-Boiron, who worked for the homeopathic laboratory for 19 years until December 2021 and has been a director since 2020, has been appointed Chairman of the Board of Directors, replacing Thierry Boiron.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about BOIRON

Boiron: changes in governance	07-04	CF
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Boiron: nearly 600,000 shares tendered to the OPAS	02-02	CF
Boiron: OPAS open from January 11 to 31	01-11	CF
Boiron: Orfim crosses the 5% threshold	23-10-13	CF
Boiron: agreement to sell majority stake signed	23-10-05	CF
Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-10	CI
Boiron: share price up, analyst raises target	23-09-07	CF
Oddo BHF Raises Boiron PT, Maintains Outperform Rating	23-09-07	MT
BOIRON : Oddo BHF raises its target price on the stock	23-09-07	CF
Boiron: 23% rise in half-year net income	23-09-07	CF
Boiron: sales down by almost 7% in 1st half-year	23-07-19	CF
Boiron: family shareholders to launch takeover bid	23-07-04	CF
Boiron: listing suspended prior to announcement	23-07-04	CF
Boiron SAÂ Board intends to launch an Equity Buyback onÂ July 4, 2023.	23-07-04	CI
Boiron: in the green after its quarterly sales figures	23-04-28	CF
Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Boiron: 56.4% increase in net income by 2022	23-03-21	CF
Boiron SA Recommends Dividend, Payable on June 3, 2023	23-03-20	CI
CAC40: day in green, week in red, close to 7000pts	23-01-20	CF
CAC40: back above 7,000, despite sharp rise in interest rates	23-01-20	CF
CAC40: flirts with 7,000, gap with US indices widens	23-01-20	CF
CAC40: back on the right foot after yesterday's plunge	23-01-20	CF
Boiron: 17% growth in annual sales	23-01-20	CF
Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI

Chart BOIRON

Duration

Period

More charts

Company Profile

Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues. Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin. There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties). BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries. Net sales are distributed geographically as follows: France (47.9%), Europe (24.7%), North America (24.4%) and other (3%).

Sector

Pharmaceuticals

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BOIRON

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

33.25 EUR

Average target price

39.6 EUR

Spread / Average Target

+19.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
BOIRON	-17.33%	625M
DONG-E-E-JIAO CO.,LTD.	+27.19%	5.56B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-33.59%	3.52B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-2.97%	3.01B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.21%	2.65B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-10.11%	2.3B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+43.66%	1.91B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+46.15%	1.5B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-13.92%	1.41B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+41.90%	1.37B

Alternative Medicine

BOIRON

Equities

BOI

FR0000061129

Pharmaceuticals

Boiron: changes in governance

Latest news about BOIRON

Chart BOIRON

Company Profile

Income Statement Evolution

Ratings for BOIRON

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Alternative Medicine